Momenta Pharmaceuticals

Momenta (NASDAQ: MNTA) develops treatments for diseases driven by autoantibodies, which are antibodies produced by the immune system that can trigger dozens of rare autoimmune conditions. The Cambridge, Massachusetts-based biotech company’s lead candidate drug, nipocalimab, is undergoing a pivotal clinical trial for warm autoimmune hemolytic anemia (WAIHA), a condition that is also a disease target for several other pharmaceutical companies.